ReviewBMC neuroscience2008
Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies.
Review in BMC neuroscience, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Shapeshifter W-Tau Peptide Inhibits Tau Aggregation and Disintegrates Paired Helical Filaments.Biochemistry · 2025Article
- Article
- PacBio Iso-Seq Improves the Rainbow Trout Genome Annotation and Identifies Alternative Splicing Associated With Economically Important Phenotypes.Frontiers in genetics · 2021Article
- PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer's Disease.Frontiers in cellular neuroscience · 2020Article
- RNA Secondary Structure-Based Design of Antisense Peptide Nucleic Acids for Modulating Disease-Associated Aberrant Tau Pre-mRNA Alternative Splicing.Molecules (Basel, Switzerland) · 2019Article
- Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease.International journal of biomedical investigation · 2018Article
- Review
- The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy.Molecular neurobiology · 2016Review
- Mitochondrial complex 1 inhibition increases 4-repeat isoform tau by SRSF2 upregulation.PloS one · 2014Article
- Neuronal-specific deficiency of the splicing factor Tra2b causes apoptosis in neurogenic areas of the developing mouse brain.PloS one · 2014Article
- Stability of clinical etiologic diagnosis in dementia and mild cognitive impairment: results from a multicenter longitudinal database.American journal of Alzheimer's disease and other dementias · 2013Article
- Splicing and alternative splicing in rice and humans.BMB reports · 2013Review
- Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention.Journal of Alzheimer's disease & Parkinsonism · 2013Article
- Phosphorylation-mediated regulation of alternative splicing in cancer.International journal of cell biology · 2013Review
- Protein tau: prime cause of synaptic and neuronal degeneration in Alzheimer's disease.International journal of Alzheimer's disease · 2012Article
- PSF suppresses tau exon 10 inclusion by interacting with a stem-loop structure downstream of exon 10.Journal of molecular neuroscience : MN · 2011Article
- Histone deacetylase activity modulates alternative splicing.PloS one · 2011Article
- FDG PET in the Evaluation of Parkinson's Disease.PET clinics · 2010Article
- Thyroid Hormone Enhances Neurite Outgrowth in Neuroscreen 1 Cells.International journal of biomedical investigationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tau aggregation is one of the major features in Alzheimer's disease and in several other tauopathies, including frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), and progressive supranuclear palsy (PSP). More than 35 mutations in the tau gene have been identified from FTDP-17 patients. A group of these mutations alters splicing of exon 10, resulting in an increase in exon 10 inclusion into tau mRNA. Abnormal splicing with inclusion of exon 10 into tau mRNA has also been observed in PSP and AD patients. These results indicate that abnormal splicing of exon 10, leading to the production of tau with exon 10, is probably one of the mechanisms by which tau accumulates and aggregates in tauopathic brains. Therefore, modulation of exon 10 splicing in the tau gene could potentially be targeted to prevent tauopathies. To identify small molecules or compounds that could potentially be developed into drugs to treat tauopathies, we established a cell-based high-throughput screening assay. In this review, we will discuss how realistic, specific biological molecules can be found to regulate exon 10 splicing in the tau gene for potential treatment of tauopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.